The National Medical Products Administration (NMPA) of China has approved ViiV Healthcare’s Vocabria (cabotegravir injection) in combination with Janssen’s Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection. Cabotegravir injection and tablets were approved in China in July 2023. Cabotegravir injection is indicated in adults who are virologically suppressed, on a stable antiretroviral (ARV) […]
